Serna Bio Analysis
What is Serna Bio?
Serna Bio builds an AI-enabled drug discovery platform that designs small molecules against RNA targets. The company says it combines machine learning, synthetic biology, and massively multiplexed screening to modulate translation and splicing. Its stated goal is to make difficult RNA biology druggable and to target the transcriptome as a drug target.
Location
Ontario, United States
Employees
1-10
Founded
2021
Business Model
AI-driven drug discovery with revenue from partnerships and licensing agreements.
Product Features & Capabilities
- small molecules that modulate translation and splicing, validated drug targets, RNA architecture mapping, functional RNA motifs, unique chemical libraries, internal programs, external collaborations
Who are the founders of Serna Bio
RK
Rabia Khan
Founder
Market Focus
Serna Bio primarily focuses on the biotechnology industry, specifically in AI-enabled drug discovery aimed at developing small molecules for challenging-to-drug targets to treat diseases with high unmet medical needs.
Investors
- Amino Collective
- Backed VC
- Lifeforce Capital
- Y Combinator
- AME Cloud Ventures
- Hummingbird Ventures
Competitors Overview
Serna Bio operates in the competitive landscape of AI-enabled drug discovery, particularly focusing on small molecules that modulate translation and splicing. Its main competitors include:
-
BioAge: This company leverages AI to identify and develop therapeutics that target aging-related diseases. Its advantage lies in its unique approach to understanding the biology of aging, which may lead to novel drug targets.
-
Insitro: Insitro combines machine learning with high-throughput biology to accelerate drug discovery. Its notable advantage is its ability to generate large datasets that can inform drug development, potentially leading to faster and more effective therapies.
-
Recursion Pharmaceuticals: Recursion uses AI to analyze cellular images and identify potential drug candidates. Its strength is in its extensive database of cellular images, which allows for innovative drug discovery approaches.
-
Tempus AI: Tempus focuses on precision medicine and uses AI to analyze clinical and molecular data. Its advantage is in its integration of real-world data with AI, which can enhance the drug discovery process.
-
XtalPi: This company utilizes AI and quantum physics to predict molecular properties and optimize drug candidates. Its unique technology allows for more accurate predictions in drug design, which can lead to better-targeted therapies.
These competitors differ from Serna Bio in their specific focus areas and methodologies, but all share the common goal of leveraging AI to improve drug discovery processes.
See something that needs updating? Suggest edits to this profile.